Header Logo

Connection

Jeremy Luban to HIV-1

Back to Details
This is a "connection" page, showing publications Jeremy Luban has written about HIV-1.
Jeremy Luban
Connection Strength
13.055
HIV-1
  1. Guney MH, Nagalekshmi K, McCauley SM, Carbone C, Aydemir O, Luban J. IFIH1 (MDA5) is required for innate immune detection of intron-containing RNA expressed from the HIV-1 provirus. Proc Natl Acad Sci U S A. 2024 Jul 16; 121(29):e2404349121.
    View in: PubMed
    Score: 0.622
  2. Wang Y, Lifshitz L, Silverstein NJ, Mintzer E, Luk K, StLouis P, Brehm MA, Wolfe SA, Deeks SG, Luban J. Transcriptional and chromatin profiling of human blood innate lymphoid cell subsets sheds light on HIV-1 pathogenesis. EMBO J. 2023 08 15; 42(16):e114153.
    View in: PubMed
    Score: 0.579
  3. Wang Y, Lifshitz L, Gellatly K, Vinton CL, Busman-Sahay K, McCauley S, Vangala P, Kim K, Derr A, Jaiswal S, Kucukural A, McDonel P, Hunt PW, Greenough T, Houghton J, Somsouk M, Estes JD, Brenchley JM, Garber M, Deeks SG, Luban J. HIV-1-induced cytokines deplete homeostatic innate lymphoid cells and expand TCF7-dependent memory NK cells. Nat Immunol. 2020 03; 21(3):274-286.
    View in: PubMed
    Score: 0.459
  4. Kim K, Dauphin A, Komurlu S, McCauley SM, Yurkovetskiy L, Carbone C, Diehl WE, Strambio-De-Castillia C, Campbell EM, Luban J. Cyclophilin A protects HIV-1 from restriction by human TRIM5a. Nat Microbiol. 2019 12; 4(12):2044-2051.
    View in: PubMed
    Score: 0.448
  5. Luban J. The hidden cost of genetic resistance to HIV-1. Nat Med. 2019 06; 25(6):878-879.
    View in: PubMed
    Score: 0.436
  6. McCauley SM, Kim K, Nowosielska A, Dauphin A, Yurkovetskiy L, Diehl WE, Luban J. Intron-containing RNA from the HIV-1 provirus activates type I interferon and inflammatory cytokines. Nat Commun. 2018 12 13; 9(1):5305.
    View in: PubMed
    Score: 0.423
  7. Luban J. Closing the net on retroviruses. Elife. 2016 07 07; 5.
    View in: PubMed
    Score: 0.357
  8. Reinhard C, Bottinelli D, Kim B, Luban J. Vpx rescue of HIV-1 from the antiviral state in mature dendritic cells is independent of the intracellular deoxynucleotide concentration. Retrovirology. 2014 Feb 01; 11:12.
    View in: PubMed
    Score: 0.302
  9. De Iaco A, Luban J. Cyclophilin A promotes HIV-1 reverse transcription but its effect on transduction correlates best with its effect on nuclear entry of viral cDNA. Retrovirology. 2014 Jan 30; 11:11.
    View in: PubMed
    Score: 0.302
  10. De Iaco A, Santoni F, Vannier A, Guipponi M, Antonarakis S, Luban J. TNPO3 protects HIV-1 replication from CPSF6-mediated capsid stabilization in the host cell cytoplasm. Retrovirology. 2013 Feb 15; 10:20.
    View in: PubMed
    Score: 0.282
  11. Luban J. Innate immune sensing of HIV-1 by dendritic cells. Cell Host Microbe. 2012 Oct 18; 12(4):408-18.
    View in: PubMed
    Score: 0.276
  12. Gr?tter MG, Luban J. TRIM5 structure, HIV-1 capsid recognition, and innate immune signaling. Curr Opin Virol. 2012 Apr; 2(2):142-50.
    View in: PubMed
    Score: 0.264
  13. De Iaco A, Luban J. Inhibition of HIV-1 infection by TNPO3 depletion is determined by capsid and detectable after viral cDNA enters the nucleus. Retrovirology. 2011 Dec 06; 8:98.
    View in: PubMed
    Score: 0.260
  14. Pertel T, Reinhard C, Luban J. Vpx rescues HIV-1 transduction of dendritic cells from the antiviral state established by type 1 interferon. Retrovirology. 2011 Jun 22; 8:49.
    View in: PubMed
    Score: 0.252
  15. Sokolskaja E, Olivari S, Zufferey M, Strambio-De-Castillia C, Pizzato M, Luban J. Cyclosporine blocks incorporation of HIV-1 envelope glycoprotein into virions. J Virol. 2010 May; 84(9):4851-5.
    View in: PubMed
    Score: 0.230
  16. Neagu MR, Ziegler P, Pertel T, Strambio-De-Castillia C, Gr?tter C, Martinetti G, Mazzucchelli L, Gr?tter M, Manz MG, Luban J. Potent inhibition of HIV-1 by TRIM5-cyclophilin fusion proteins engineered from human components. J Clin Invest. 2009 Oct; 119(10):3035-47.
    View in: PubMed
    Score: 0.222
  17. Luban J. HIV-1 infection: going nuclear with TNPO3/Transportin-SR2 and integrase. Curr Biol. 2008 Aug 26; 18(16):R710-3.
    View in: PubMed
    Score: 0.207
  18. Berthoux L, Sebastian S, Muesing MA, Luban J. The role of lysine 186 in HIV-1 integrase multimerization. Virology. 2007 Jul 20; 364(1):227-36.
    View in: PubMed
    Score: 0.188
  19. Luban J. Cyclophilin A, TRIM5, and resistance to human immunodeficiency virus type 1 infection. J Virol. 2007 Feb; 81(3):1054-61.
    View in: PubMed
    Score: 0.181
  20. Sokolskaja E, Luban J. Cyclophilin, TRIM5, and innate immunity to HIV-1. Curr Opin Microbiol. 2006 Aug; 9(4):404-8.
    View in: PubMed
    Score: 0.178
  21. Sokolskaja E, Berthoux L, Luban J. Cyclophilin A and TRIM5alpha independently regulate human immunodeficiency virus type 1 infectivity in human cells. J Virol. 2006 Mar; 80(6):2855-62.
    View in: PubMed
    Score: 0.174
  22. Sebastian S, Sokolskaja E, Luban J. Arsenic counteracts human immunodeficiency virus type 1 restriction by various TRIM5 orthologues in a cell type-dependent manner. J Virol. 2006 Feb; 80(4):2051-4.
    View in: PubMed
    Score: 0.173
  23. Berthoux L, Sebastian S, Sokolskaja E, Luban J. Cyclophilin A is required for TRIM5{alpha}-mediated resistance to HIV-1 in Old World monkey cells. Proc Natl Acad Sci U S A. 2005 Oct 11; 102(41):14849-53.
    View in: PubMed
    Score: 0.169
  24. Berthoux L, Sebastian S, Sayah DM, Luban J. Disruption of human TRIM5alpha antiviral activity by nonhuman primate orthologues. J Virol. 2005 Jun; 79(12):7883-8.
    View in: PubMed
    Score: 0.165
  25. Gurer C, H?glund A, H?glund S, Luban J. ATPgammaS disrupts human immunodeficiency virus type 1 virion core integrity. J Virol. 2005 May; 79(9):5557-67.
    View in: PubMed
    Score: 0.164
  26. Gurer C, Berthoux L, Luban J. Covalent modification of human immunodeficiency virus type 1 p6 by SUMO-1. J Virol. 2005 Jan; 79(2):910-7.
    View in: PubMed
    Score: 0.161
  27. Sokolskaja E, Sayah DM, Luban J. Target cell cyclophilin A modulates human immunodeficiency virus type 1 infectivity. J Virol. 2004 Dec; 78(23):12800-8.
    View in: PubMed
    Score: 0.160
  28. Berthoux L, Sebastian S, Sokolskaja E, Luban J. Lv1 inhibition of human immunodeficiency virus type 1 is counteracted by factors that stimulate synthesis or nuclear translocation of viral cDNA. J Virol. 2004 Nov; 78(21):11739-50.
    View in: PubMed
    Score: 0.159
  29. Sayah DM, Luban J. Selection for loss of Ref1 activity in human cells releases human immunodeficiency virus type 1 from cyclophilin A dependence during infection. J Virol. 2004 Nov; 78(21):12066-70.
    View in: PubMed
    Score: 0.159
  30. Padron A, Dwivedi R, Chakraborty R, Prakash P, Kim K, Shi J, Ahn J, Pandhare J, Luban J, Aiken C, Balasubramaniam M, Dash C. Cyclophilin A facilitates HIV-1 integration. J Virol. 2024 Nov 19; 98(11):e0094724.
    View in: PubMed
    Score: 0.159
  31. Padron A, Prakash P, Pandhare J, Luban J, Aiken C, Balasubramaniam M, Dash C. Emerging role of cyclophilin A in HIV-1 infection: from producer cell to the target cell nucleus. J Virol. 2023 11 30; 97(11):e0073223.
    View in: PubMed
    Score: 0.148
  32. Xue G, Yu HJ, Buffone C, Huang SW, Lee K, Goh SL, Gres AT, Guney MH, Sarafianos SG, Luban J, Diaz-Griffero F, KewalRamani VN. The HIV-1 capsid core is an opportunistic nuclear import receptor. Nat Commun. 2023 06 24; 14(1):3782.
    View in: PubMed
    Score: 0.145
  33. Berthoux L, Towers GJ, Gurer C, Salomoni P, Pandolfi PP, Luban J. As(2)O(3) enhances retroviral reverse transcription and counteracts Ref1 antiviral activity. J Virol. 2003 Mar; 77(5):3167-80.
    View in: PubMed
    Score: 0.141
  34. Luban J. HIV-1 and Ebola virus: the getaway driver nabbed. Nat Med. 2001 Dec; 7(12):1278-80.
    View in: PubMed
    Score: 0.130
  35. Cimarelli A, Luban J. Context-dependent phenotype of a human immunodeficiency virus type 1 nucleocapsid mutation. J Virol. 2001 Aug; 75(15):7193-7.
    View in: PubMed
    Score: 0.127
  36. Diehl WE, Guney MH, Vanzo T, Kyawe PP, White JM, Pizzato M, Luban J. Influence of Different Glycoproteins and of the Virion Core on SERINC5 Antiviral Activity. Viruses. 2021 06 30; 13(7).
    View in: PubMed
    Score: 0.126
  37. Braaten D, Luban J. Cyclophilin A regulates HIV-1 infectivity, as demonstrated by gene targeting in human T cells. EMBO J. 2001 Mar 15; 20(6):1300-9.
    View in: PubMed
    Score: 0.123
  38. Cimarelli A, Luban J. Human immunodeficiency virus type 1 virion density is not determined by nucleocapsid basic residues. J Virol. 2000 Aug; 74(15):6734-40.
    View in: PubMed
    Score: 0.118
  39. Cimarelli A, Sandin S, H?glund S, Luban J. Rescue of multiple viral functions by a second-site suppressor of a human immunodeficiency virus type 1 nucleocapsid mutation. J Virol. 2000 May; 74(9):4273-83.
    View in: PubMed
    Score: 0.116
  40. Ohainle M, Kim K, Komurlu Keceli S, Felton A, Campbell E, Luban J, Emerman M. TRIM34 restricts HIV-1 and SIV capsids in a TRIM5a-dependent manner. PLoS Pathog. 2020 04; 16(4):e1008507.
    View in: PubMed
    Score: 0.116
  41. Cimarelli A, Sandin S, H?glund S, Luban J. Basic residues in human immunodeficiency virus type 1 nucleocapsid promote virion assembly via interaction with RNA. J Virol. 2000 Apr; 74(7):3046-57.
    View in: PubMed
    Score: 0.116
  42. Burniston MT, Cimarelli A, Colgan J, Curtis SP, Luban J. Human immunodeficiency virus type 1 Gag polyprotein multimerization requires the nucleocapsid domain and RNA and is promoted by the capsid-dimer interface and the basic region of matrix protein. J Virol. 1999 Oct; 73(10):8527-40.
    View in: PubMed
    Score: 0.112
  43. Cimarelli A, Luban J. Translation elongation factor 1-alpha interacts specifically with the human immunodeficiency virus type 1 Gag polyprotein. J Virol. 1999 Jul; 73(7):5388-401.
    View in: PubMed
    Score: 0.110
  44. Boucher JI, Whitfield TW, Dauphin A, Nachum G, Hollins C, Zeldovich KB, Swanstrom R, Schiffer CA, Luban J, Bolon DNA. Constrained Mutational Sampling of Amino Acids in HIV-1 Protease Evolution. Mol Biol Evol. 2019 04 01; 36(4):798-810.
    View in: PubMed
    Score: 0.108
  45. Gawron MA, Duval M, Carbone C, Jaiswal S, Wallace A, Martin JC, Dauphin A, Brehm MA, Greiner DL, Shultz LD, Luban J, Cavacini LA. Human Anti-HIV-1 gp120 Monoclonal Antibodies with Neutralizing Activity Cloned from Humanized Mice Infected with HIV-1. J Immunol. 2019 02 01; 202(3):799-804.
    View in: PubMed
    Score: 0.106
  46. Yurkovetskiy L, Guney MH, Kim K, Goh SL, McCauley S, Dauphin A, Diehl WE, Luban J. Primate immunodeficiency virus proteins Vpx and Vpr counteract transcriptional repression of proviruses by the HUSH complex. Nat Microbiol. 2018 12; 3(12):1354-1361.
    View in: PubMed
    Score: 0.104
  47. Yin L, Braaten D, Luban J. Human immunodeficiency virus type 1 replication is modulated by host cyclophilin A expression levels. J Virol. 1998 Aug; 72(8):6430-6.
    View in: PubMed
    Score: 0.103
  48. Morger D, Zosel F, B?hlmann M, Z?ger S, Mittelviefhaus M, Schuler B, Luban J, Gr?tter MG. The Three-Fold Axis of the HIV-1 Capsid Lattice Is the Species-Specific Binding Interface for TRIM5a. J Virol. 2018 03 01; 92(5).
    View in: PubMed
    Score: 0.100
  49. Quitadamo B, Peters PJ, Repik A, O'Connell O, Mou Z, Koch M, Somasundaran M, Brody R, Luzuriaga K, Wallace A, Wang S, Lu S, McCauley S, Luban J, Duenas-Decamp M, Gonzalez-Perez MP, Clapham PR. HIV-1 R5 Macrophage-Tropic Envelope Glycoprotein Trimers Bind CD4 with High Affinity, while the CD4 Binding Site on Non-macrophage-tropic, T-Tropic R5 Envelopes Is Occluded. J Virol. 2018 01 15; 92(2).
    View in: PubMed
    Score: 0.099
  50. Yin L, Boussard S, Allan J, Luban J. The HIV type 1 replication block in nonhuman primates is not explained by differences in cyclophilin A primary structure. AIDS Res Hum Retroviruses. 1998 Jan 01; 14(1):95-7.
    View in: PubMed
    Score: 0.099
  51. Braaten D, Ansari H, Luban J. The hydrophobic pocket of cyclophilin is the binding site for the human immunodeficiency virus type 1 Gag polyprotein. J Virol. 1997 Mar; 71(3):2107-13.
    View in: PubMed
    Score: 0.093
  52. Re F, Luban J. HIV-1 Vpr: G2 cell cycle arrest, macrophages and nuclear transport. Prog Cell Cycle Res. 1997; 3:21-7.
    View in: PubMed
    Score: 0.092
  53. Luban J. Absconding with the chaperone: essential cyclophilin-Gag interaction in HIV-1 virions. Cell. 1996 Dec 27; 87(7):1157-9.
    View in: PubMed
    Score: 0.092
  54. Braaten D, Aberham C, Franke EK, Yin L, Phares W, Luban J. Cyclosporine A-resistant human immunodeficiency virus type 1 mutants demonstrate that Gag encodes the functional target of cyclophilin A. J Virol. 1996 Aug; 70(8):5170-6.
    View in: PubMed
    Score: 0.090
  55. Franke EK, Luban J. Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag-cyclophilin A interaction. Virology. 1996 Aug 01; 222(1):279-82.
    View in: PubMed
    Score: 0.090
  56. Braaten D, Franke EK, Luban J. Cyclophilin A is required for the replication of group M human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus SIV(CPZ)GAB but not group O HIV-1 or other primate immunodeficiency viruses. J Virol. 1996 Jul; 70(7):4220-7.
    View in: PubMed
    Score: 0.089
  57. Colgan J, Yuan HE, Franke EK, Luban J. Binding of the human immunodeficiency virus type 1 Gag polyprotein to cyclophilin A is mediated by the central region of capsid and requires Gag dimerization. J Virol. 1996 Jul; 70(7):4299-310.
    View in: PubMed
    Score: 0.089
  58. Braaten D, Franke EK, Luban J. Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription. J Virol. 1996 Jun; 70(6):3551-60.
    View in: PubMed
    Score: 0.089
  59. Chen NY, Zhou L, Gane PJ, Opp S, Ball NJ, Nicastro G, Zufferey M, Buffone C, Luban J, Selwood D, Diaz-Griffero F, Taylor I, Fassati A. HIV-1 capsid is involved in post-nuclear entry steps. Retrovirology. 2016 Apr 23; 13:28.
    View in: PubMed
    Score: 0.088
  60. Re F, Braaten D, Franke EK, Luban J. Human immunodeficiency virus type 1 Vpr arrests the cell cycle in G2 by inhibiting the activation of p34cdc2-cyclin B. J Virol. 1995 Nov; 69(11):6859-64.
    View in: PubMed
    Score: 0.085
  61. Rosa A, Chande A, Ziglio S, De Sanctis V, Bertorelli R, Goh SL, McCauley SM, Nowosielska A, Antonarakis SE, Luban J, Santoni FA, Pizzato M. HIV-1 Nef promotes infection by excluding SERINC5 from virion incorporation. Nature. 2015 Oct 08; 526(7572):212-7.
    View in: PubMed
    Score: 0.085
  62. Franke EK, Chen BX, Tatsis I, Diamanduros A, Erlanger BF, Luban J. Cyclophilin binding to the human immunodeficiency virus type 1 Gag polyprotein is mimicked by an anti-cyclosporine antibody. J Virol. 1995 Sep; 69(9):5821-3.
    View in: PubMed
    Score: 0.084
  63. Franke EK, Luban J. Cyclophilin and gag in HIV-1 replication and pathogenesis. Adv Exp Med Biol. 1995; 374:217-28.
    View in: PubMed
    Score: 0.080
  64. Franke EK, Yuan HE, Luban J. Specific incorporation of cyclophilin A into HIV-1 virions. Nature. 1994 Nov 24; 372(6504):359-62.
    View in: PubMed
    Score: 0.080
  65. Luban J, Goff SP. Mutational analysis of cis-acting packaging signals in human immunodeficiency virus type 1 RNA. J Virol. 1994 Jun; 68(6):3784-93.
    View in: PubMed
    Score: 0.077
  66. Singh R, Patel V, Mureithi MW, Naranbhai V, Ramsuran D, Tulsi S, Hiramen K, Werner L, Mlisana K, Altfeld M, Luban J, Kasprowicz V, Dheda K, Abdool Karim SS, Ndung'u T. TRIM5a and TRIM22 are differentially regulated according to HIV-1 infection phase and compartment. J Virol. 2014 Apr; 88(8):4291-303.
    View in: PubMed
    Score: 0.075
  67. Yang Y, Luban J, Diaz-Griffero F. The fate of HIV-1 capsid: a biochemical assay for HIV-1 uncoating. Methods Mol Biol. 2014; 1087:29-36.
    View in: PubMed
    Score: 0.075
  68. Brehm MA, Shultz LD, Luban J, Greiner DL. Overcoming current limitations in humanized mouse research. J Infect Dis. 2013 Nov; 208 Suppl 2:S125-30.
    View in: PubMed
    Score: 0.074
  69. Xu H, Franks T, Gibson G, Huber K, Rahm N, Strambio De Castillia C, Luban J, Aiken C, Watkins S, Sluis-Cremer N, Ambrose Z. Evidence for biphasic uncoating during HIV-1 infection from a novel imaging assay. Retrovirology. 2013 Jul 09; 10:70.
    View in: PubMed
    Score: 0.073
  70. Luban J, Bossolt KL, Franke EK, Kalpana GV, Goff SP. Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell. 1993 Jun 18; 73(6):1067-78.
    View in: PubMed
    Score: 0.072
  71. Luban J, Lee C, Goff SP. Effect of linker insertion mutations in the human immunodeficiency virus type 1 gag gene on activation of viral protease expressed in bacteria. J Virol. 1993 Jun; 67(6):3630-4.
    View in: PubMed
    Score: 0.072
  72. Uchil PD, Hinz A, Siegel S, Coenen-Stass A, Pertel T, Luban J, Mothes W. TRIM protein-mediated regulation of inflammatory and innate immune signaling and its association with antiretroviral activity. J Virol. 2013 Jan; 87(1):257-72.
    View in: PubMed
    Score: 0.069
  73. Luban J, Alin KB, Bossolt KL, Humaran T, Goff SP. Genetic assay for multimerization of retroviral gag polyproteins. J Virol. 1992 Aug; 66(8):5157-60.
    View in: PubMed
    Score: 0.068
  74. Lai RP, Yan J, Heeney J, McClure MO, G?ttlinger H, Luban J, Pizzato M. Nef decreases HIV-1 sensitivity to neutralizing antibodies that target the membrane-proximal external region of TMgp41. PLoS Pathog. 2011 Dec; 7(12):e1002442.
    View in: PubMed
    Score: 0.065
  75. Lukic Z, Hausmann S, Sebastian S, Rucci J, Sastri J, Robia SL, Luban J, Campbell EM. TRIM5a associates with proteasomal subunits in cells while in complex with HIV-1 virions. Retrovirology. 2011 Nov 12; 8:93.
    View in: PubMed
    Score: 0.065
  76. Luban J, Goff SP. Binding of human immunodeficiency virus type 1 (HIV-1) RNA to recombinant HIV-1 gag polyprotein. J Virol. 1991 Jun; 65(6):3203-12.
    View in: PubMed
    Score: 0.063
  77. Pertel T, Hausmann S, Morger D, Z?ger S, Guerra J, Lascano J, Reinhard C, Santoni FA, Uchil PD, Chatel L, Bisiaux A, Albert ML, Strambio-De-Castillia C, Mothes W, Pizzato M, Gr?tter MG, Luban J. TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature. 2011 Apr 21; 472(7343):361-5.
    View in: PubMed
    Score: 0.062
  78. Kajaste-Rudnitski A, Marelli SS, Pultrone C, Pertel T, Uchil PD, Mechti N, Mothes W, Poli G, Luban J, Vicenzi E. TRIM22 inhibits HIV-1 transcription independently of its E3 ubiquitin ligase activity, Tat, and NF-kappaB-responsive long terminal repeat elements. J Virol. 2011 May; 85(10):5183-96.
    View in: PubMed
    Score: 0.062
  79. Singh R, Gaiha G, Werner L, McKim K, Mlisana K, Luban J, Walker BD, Karim SS, Brass AL, Ndung'u T. Association of TRIM22 with the type 1 interferon response and viral control during primary HIV-1 infection. J Virol. 2011 Jan; 85(1):208-16.
    View in: PubMed
    Score: 0.060
  80. Strebel K, Luban J, Jeang KT. Human cellular restriction factors that target HIV-1 replication. BMC Med. 2009 Sep 16; 7:48.
    View in: PubMed
    Score: 0.056
  81. Mangeat B, Gers-Huber G, Lehmann M, Zufferey M, Luban J, Piguet V. HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation. PLoS Pathog. 2009 Sep; 5(9):e1000574.
    View in: PubMed
    Score: 0.056
  82. Sayah DM, Sokolskaja E, Berthoux L, Luban J. Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature. 2004 Jul 29; 430(6999):569-73.
    View in: PubMed
    Score: 0.039
  83. Towers GJ, Hatziioannou T, Cowan S, Goff SP, Luban J, Bieniasz PD. Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nat Med. 2003 Sep; 9(9):1138-43.
    View in: PubMed
    Score: 0.036
  84. Zhang YJ, Hatziioannou T, Zang T, Braaten D, Luban J, Goff SP, Bieniasz PD. Envelope-dependent, cyclophilin-independent effects of glycosaminoglycans on human immunodeficiency virus type 1 attachment and infection. J Virol. 2002 Jun; 76(12):6332-43.
    View in: PubMed
    Score: 0.034
  85. Gurer C, Cimarelli A, Luban J. Specific incorporation of heat shock protein 70 family members into primate lentiviral virions. J Virol. 2002 May; 76(9):4666-70.
    View in: PubMed
    Score: 0.033
  86. Reicin AS, Paik S, Berkowitz RD, Luban J, Lowy I, Goff SP. Linker insertion mutations in the human immunodeficiency virus type 1 gag gene: effects on virion particle assembly, release, and infectivity. J Virol. 1995 Feb; 69(2):642-50.
    View in: PubMed
    Score: 0.020
  87. Berkowitz RD, Luban J, Goff SP. Specific binding of human immunodeficiency virus type 1 gag polyprotein and nucleocapsid protein to viral RNAs detected by RNA mobility shift assays. J Virol. 1993 Dec; 67(12):7190-200.
    View in: PubMed
    Score: 0.019
  88. Dorfman T, Luban J, Goff SP, Haseltine WA, G?ttlinger HG. Mapping of functionally important residues of a cysteine-histidine box in the human immunodeficiency virus type 1 nucleocapsid protein. J Virol. 1993 Oct; 67(10):6159-69.
    View in: PubMed
    Score: 0.018
  89. Miyamoto T, Nakayama EE, Yokoyama M, Ibe S, Takehara S, Kono K, Yokomaku Y, Pizzato M, Luban J, Sugiura W, Sato H, Shioda T. The carboxyl-terminus of human immunodeficiency virus type 2 circulating recombinant form 01_AB capsid protein affects sensitivity to human TRIM5a. PLoS One. 2012; 7(10):e47757.
    View in: PubMed
    Score: 0.017
  90. O'Connor C, Pertel T, Gray S, Robia SL, Bakowska JC, Luban J, Campbell EM. p62/sequestosome-1 associates with and sustains the expression of retroviral restriction factor TRIM5alpha. J Virol. 2010 Jun; 84(12):5997-6006.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.